TOPICAL TREATMENT FOR PREVENTING AND MITIGATING SKIN CYTOTOXICITY DUE TO THERAPY WITH TYROSINE KINASE INHIBITORS

摘要

The invention relates to the use of a topical preparation based on 3,4,5'-trihydroxystilbene-3-p-mono-d-glucoside (polydatin or piceid, or resvera- trol-3-β-mono-D-glucoside) a glycosylated derivative of resveratrol, for the prophylaxis and management of adverse skin and mucosal reactions in the therapy with tyrosine kinase inhibitor antitumor drugs, in particular tyrosine kinase inhibitors of EGF receptors (EGFR-TKI ). The prophylaxis is performed by applying a polydatin-based topical preparation to the skin and/or mucous membranes at least once a day and before administration of the antitumor drug, to protect the skin from adverse effects of the anticancer treatment, such as skin rash, acneiform dermatitis, itch- ing, ungual alterations, cutaneous xerosis or stomatitis.